Cargando…

Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring

AZD7442, a combination of two long-acting monoclonal antibodies (tixagevimab [AZD8895] and cilgavimab [AZD1061]), has been authorized for the prevention and treatment of coronavirus disease 2019 (COVID-19). The rapid emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brady, Tyler, Zhang, Tianhui, Tuffy, Kevin M., Haskins, Nantaporn, Du, Qun, Lin, Jia, Kaplan, Gilad, Novick, Steven, Roe, Tiffany L., Ren, Kuishu, Rosenthal, Kim, McTamney, Patrick M., Abram, Michael E., Streicher, Katie, Kelly, Elizabeth J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704045/ https://www.ncbi.nlm.nih.gov/pubmed/35993765 http://dx.doi.org/10.1128/spectrum.01034-22

Ejemplares similares

Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants
por: Roe, Tiffany L., et al.
Publicado: (2023)

Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants
por: Tuffy, Kevin M, et al.
Publicado: (2023)

The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans
por: Loo, Yueh-Ming, et al.
Publicado: (2022)

Kinetic Titration Series with Biolayer Interferometry
por: Frenzel, Daniel, et al.
Publicado: (2014)

Biolayer interferometry for DNA-protein interactions
por: Barrows, John K., et al.
Publicado: (2022)

1143. Prophylactic and Therapeutic Activity of AZD7442 (Tixagevimab/Cilgavimab) in SARS-CoV-2 Hamster Challenge Models
por: Loo, Yueh-Ming, et al.
Publicado: (2022)

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
por: Levin, Myron J., et al.
Publicado: (2022)

Characterization of antibody-antigen interactions using biolayer interferometry
por: Noy-Porat, Tal, et al.
Publicado: (2021)

Influenza vaccine titer determination using biolayer interferometry (BLI)
por: Wheatley, David W, et al.
Publicado: (2015)

Measuring the effects of macromolecular crowding on antibody function with biolayer interferometry
por: Kim, Dorothy M., et al.
Publicado: (2019)

Applications of Surface Plasmon Resonance and Biolayer Interferometry for Virus–Ligand Binding
por: Murali, Shruthi, et al.
Publicado: (2022)

AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019
por: Levin, Myron J, et al.
Publicado: (2022)

Rapid and sensitive detection of SARS-CoV-2 antibodies by biolayer interferometry
por: Dzimianski, John V., et al.
Publicado: (2020)

Rapid and sensitive detection of SARS-CoV-2 antibodies by biolayer interferometry
por: Dzimianski, John V., et al.
Publicado: (2020)

On-Site Biolayer Interferometry-Based Biosensing of Carbamazepine in Whole Blood of Epileptic Patients
por: Bian, Sumin, et al.
Publicado: (2021)

Suppressing Nonspecific Binding in Biolayer Interferometry Experiments for Weak Ligand–Analyte Interactions
por: Dubrow, Alyssa, et al.
Publicado: (2022)

Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains
por: Case, James Brett, et al.
Publicado: (2022)

1354. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of COVID-19: 15-Month Final Analysis of the PROVENT Phase 3 Study
por: Levin, Myron J, et al.
Publicado: (2023)

Biolayer Interferometry Analysis for a Higher Throughput Quantification of In-Process Samples of a Rotavirus Vaccine
por: Carvalho, Sofia B., et al.
Publicado: (2022)

Low serum neutralization of Omicron variants a month after AZD7442 prophylaxis initiation
por: de Lamballerie, Xavier, et al.
Publicado: (2023)

Evaluating the immunogenicity of heparin and heparin derivatives by measuring their binding to platelet factor 4 using biolayer interferometry
por: Chen, Qingqing, et al.
Publicado: (2022)

1353. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of COVID-19: Final Analysis of the STORM CHASER Phase 3 Study
por: Levin, Myron J, et al.
Publicado: (2023)

529. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Phase 3 Study
por: Richard Hobbs, F D, et al.
Publicado: (2023)

Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with Plasmodium falciparum Circumsporozoite Protein Antigens
por: Dennison, S. Moses, et al.
Publicado: (2018)

Rapid Biolayer Interferometry Measurements of Urinary CXCL9 to Detect Cellular Infiltrates Noninvasively After Kidney Transplantation
por: Gandolfini, Ilaria, et al.
Publicado: (2017)

Biolayer interferometry predicts ELISA performance of monoclonal antibody pairs for Plasmodium falciparum histidine-rich protein 2
por: Markwalter, C.F., et al.
Publicado: (2017)

2LTRZFP Interacts Specifically to HIV-1 DNA without Off-Target Effects as Determined by Biolayer Interferometry
por: Chupradit, Koollawat, et al.
Publicado: (2021)

LB5. PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 in Adults
por: Levin, Myron J, et al.
Publicado: (2021)

Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies
por: Stuver, Robert, et al.
Publicado: (2022)

AZD7442 utilization for Pre-Exposure Prophylaxis Against COVID-19 in a French Early Access Program
por: Artaud, C, et al.
Publicado: (2023)

Comparison of Enzyme-Linked Immunosorbent Assay, Surface Plasmon Resonance and Biolayer Interferometry for Screening of Deoxynivalenol in Wheat and Wheat Dust
por: Sanders, Melanie, et al.
Publicado: (2016)

Potency determination of inactivated H7 influenza vaccines using monoclonal antibody‐based ELISA and biolayer interferometry assays
por: Vasudevan, Anupama, et al.
Publicado: (2017)

Analyzing Dynamic Protein Complexes Assembled On and Released From Biolayer Interferometry Biosensor Using Mass Spectrometry and Electron Microscopy
por: Machen, Alexandra J., et al.
Publicado: (2018)

Biophysical Characterization of the Oligomeric States of Recombinant Immunoglobulins Type-M and Their C1q-Binding Kinetics by Biolayer Interferometry
por: Chouquet, Anne, et al.
Publicado: (2022)

Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial
por: Hobbs, F. D. Richard, et al.
Publicado: (2023)

2733. Evusheld (AZD7442) Uptake and COVID-19 Outcomes in Solid Organ Transplant Recipients: A Secondary Analysis
por: Hayek, Haya, et al.
Publicado: (2023)

Fragment screening using biolayer interferometry reveals ligands targeting the SHP-motif binding site of the AAA+ ATPase p97
por: Bothe, Sebastian, et al.
Publicado: (2022)

Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults
por: Forte-Soto, Pablo, et al.
Publicado: (2023)

A scalable and high yielding SARS-CoV-2 spike protein receptor binding domain production process
por: Riguero, Valeria, et al.
Publicado: (2023)

Profile of patients with chemical injury and sensitivity.
por: Ziem, G, et al.
Publicado: (1997)

Cannot write session to /tmp/vufind_sessions/sess_28hbdsv2b2m51f03g3e4j2i026